Professor Guo Jiao's team and Li Hongliang's team at Wuhan University have shown that statins can significantly reduce the mortality rate of patients with new coronary pneumonia

On June 24 , a study published on Cell Metabolism ( IF: 21.567 ) by Guo Jiao’s team from the Provincial Research Center for Metabolic Diseases Integrative Traditional Chinese and Western Medicine and Li Hongliang’s team from Wuhan University pointed out that the use of statins can significantly reduce the risk of death in patients with new coronary pneumonia. mortality rate. Through a retrospective study of 13,981 patients with new coronary pneumonia in 21 hospitals in Hubei Province, the researchers found that the research data after strict matching and correction showed that the 28- day all-cause mortality rate of the statin group was 5.2% , which was significantly lower than that of the statin group. The mortality rate was 9.4% in the non-statin group . This shows the special importance of clinical control of glucose and lipid metabolic diseases for the clinical treatment of new coronary pneumonia.

The results of the study showed that in patients with new coronary pneumonia and hypertension, the combination therapy of statins and pril / sartan drugs did not increase the risk of death and other secondary outcomes of patients compared with the combination therapy with other antihypertensive drugs risks of. This study provides important supporting evidence for the effectiveness and safety of this type of drug combination in the treatment of patients with new coronary pneumonia, and clearly supports the effectiveness and significant protective effect of statins in hospitalized patients with new coronary pneumonia. Statin-related research provides evidence and confidence.

 https://www.gdkjb.com/view-12310.html?from=singlemessage